Press release
Idiopathic Pulmonary Fibrosis Pipeline, Clinical Trials, NDA Approvals, and Emerging Drugs (2023) | Companies- Roche, Novartis, Vicore Pharma, and Others
Idiopathic Pulmonary Fibrosis Pipeline
In the Idiopathic Pulmonary Fibrosis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Idiopathic Pulmonary Fibrosis NDA approvals (if any), and product development activities comprising the technology, Idiopathic Pulmonary Fibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Idiopathic Pulmonary Fibrosis Pipeline treatment landscape of the report, click here @ Idiopathic Pulmonary Fibrosis Pipeline Outlook- https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Insight Report
• DelveInsight's analysis presents Idiopathic Pulmonary Fibrosis Pipeline with 80+ active players in the domain investigating 80+ pipeline therapies.
• The leading Idiopathic Pulmonary Fibrosis Companies include Mission Therapeutics, Lung Therapeutics, Theravance Biopharma, Pliant Therapeutics, Vicore Pharma, Galecto Biotech, FibroGen, Roche, Kinarus, Insmed, Avalyn Pharmaceuticals, Bridge Biotherapeutics, and others.
• Promising Idiopathic Pulmonary Fibrosis pipeline therapies include DUB program: USP30 Inhibitor, LTI-03, TD-1058, PLN-74809, C21, GB0139, Pamrevlumab, PRM-151, KIN001-IPF, Treprostinil palmitil, AP01, BBT-877, and others.
• On February 2022, Endeavor BioMedicines, announced the completion of a $101 million Series B financing, led by Ally Bridge Group and Avidity Partners. New investors participating in the round include Perceptive Advisors, Piper Heartland Healthcare Capital, Revelation Partners, funds managed by Tekla Capital Management LLC, and funds and accounts advised by T. Rowe Price Associates, Inc. Existing investors Omega Funds and Longitude Capital also participated. Proceeds will support the advancement of Endeavor's pipeline programs, including ENV-101 (taladegib), a small molecule inhibitor of the PTCH1 receptor in the Hedgehog signaling pathway for the treatment of cancer and idiopathic pulmonary fibrosis (IPF), as well as ENV-201, a potentially best-in-class small molecule inhibitor of ULK1/2 for the treatment of KRAS-driven cancers.
Idiopathic Pulmonary Fibrosis Overview
Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia that is found to affect the middle-aged and older adults; and affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis) which increases irreversibly over time.
For further information, refer to the detailed Idiopathic Pulmonary Fibrosis Unmet Needs, Idiopathic Pulmonary Fibrosis Market Drivers, and Idiopathic Pulmonary Fibrosis Market Barriers, click here for Idiopathic Pulmonary Fibrosis Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Idiopathic Pulmonary Fibrosis Emerging Drugs Profile
• PRM-151: Hoffmann-La Roche
• Pamrevlumab: FibroGen
• Tipelukast: MediciNova
• PLN-74809: Pliant Therapeutics
• GLPG4716: Galapagos NV
Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment
There are approx. 80+ Idiopathic Pulmonary Fibrosis companies which are developing the therapies for Idiopathic Pulmonary Fibrosis. The Idiopathic Pulmonary Fibrosis companies which have their Idiopathic Pulmonary Fibrosis drug candidates in the most advanced stage, i.e. phase III include, Hoffmann-La Roche.
Request a sample and discover the recent advances in Idiopathic Pulmonary Fibrosis Ongoing Clinical Trial Analysis and Medications, click here @ Idiopathic Pulmonary Fibrosis Treatment Landscape- https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Idiopathic Pulmonary Fibrosis Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Idiopathic Pulmonary Fibrosis Therapeutics Market include-
Mission Therapeutics, Lung Therapeutics, Theravance Biopharma, Pliant Therapeutics, Vicore Pharma, Galecto Biotech, FibroGen, Roche, Kinarus, Insmed, Avalyn Pharmaceuticals, Bridge Biotherapeutics, and others.
Dive deep into rich insights for drugs for Idiopathic Pulmonary Fibrosis Pipeline, click here @ Idiopathic Pulmonary Fibrosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Idiopathic Pulmonary Fibrosis Pipeline Report
• Coverage- Global
• Idiopathic Pulmonary Fibrosis Companies- Mission Therapeutics, Lung Therapeutics, Theravance Biopharma, Pliant Therapeutics, Vicore Pharma, Galecto Biotech, FibroGen, Roche, Kinarus, Insmed, Avalyn Pharmaceuticals, Bridge Biotherapeutics, and others
• Idiopathic Pulmonary Fibrosis Pipeline Therapies- DUB program: USP30 Inhibitor, LTI-03, TD-1058, PLN-74809, C21, GB0139, Pamrevlumab, PRM-151, KIN001-IPF, Treprostinil palmitic, AP01, BBT-877, and others
• Idiopathic Pulmonary Fibrosis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Idiopathic Pulmonary Fibrosis Merger and acquisitions, Idiopathic Pulmonary Fibrosis Licensing Activities @ Idiopathic Pulmonary Fibrosis Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Idiopathic Pulmonary Fibrosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Idiopathic Pulmonary Fibrosis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. PRM-151: Hoffmann-La Roche
9. Mid Stage Products (Phase II)
10. Tipelukast: MediciNova
11. Early Stage Products (Phase I/II)
12. Lung stem cells: Regend Therapeutics
13. Early Stage Products (Phase I)
14. LTI-03: Lung Therapeutics
15. Preclinical and Discovery Stage Products
16. AD-214: Adalta
17. Inactive Products
18. Idiopathic Pulmonary Fibrosis Key Companies
19. Idiopathic Pulmonary Fibrosis Key Products
20. Idiopathic Pulmonary Fibrosis- Unmet Needs
21. Idiopathic Pulmonary Fibrosis- Market Drivers and Barriers
22. Idiopathic Pulmonary Fibrosis- Future Perspectives and Conclusion
23. Idiopathic Pulmonary Fibrosis Analyst Views
24. Idiopathic Pulmonary Fibrosis Key Companies
25. Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/conference-coverage-car-tcr-summit
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Idiopathic Pulmonary Fibrosis Pipeline, Clinical Trials, NDA Approvals, and Emerging Drugs (2023) | Companies- Roche, Novartis, Vicore Pharma, and Others here
News-ID: 3094882 • Views: …
More Releases from DelveInsight Business Research
Primary Biliary Cholangitis Market Expected to Experience Major Growth by 2034, …
DelveInsight's "Primary Biliary Cholangitis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Primary Biliary Cholangitis, historical and forecasted epidemiology as well as the Primary Biliary Cholangitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Primary Biliary Cholangitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Primary Biliary Cholangitis…
Advanced Renal Cell Carcinoma Pipeline 2025: Therapies, MOA Insights, and Key Cl …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Advanced Renal Cell Carcinoma pipeline constitutes 50+ key companies continuously working towards developing 60+ Advanced Renal Cell Carcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Advanced Renal Cell Carcinoma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across…
Alport Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis b …
DelveInsight's "Alport Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Alport Syndrome, historical and forecasted epidemiology as well as the Alport Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Alport Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alport Syndrome Market Forecast
https://www.delveinsight.com/sample-request/alport-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Angioedema Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA a …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Angioedema pipeline constitutes 20+ key companies continuously working towards developing 20+ Angioedema treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Angioedema Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
More Releases for Idiopathic
Idiopathic Pulmonary Fibrosis Market Size & Share Analysis
The new report published by The Business Research Company, titled Idiopathic Pulmonary Fibrosis Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the idiopathic pulmonary fibrosis market size has grown strongly in recent years. It will grow from $3.89…
Charting New Frontiers: Idiopathic Gastroparesis Drugs Market Dynamics
The Idiopathic Gastroparesis Drugs Market 𝐑𝐞𝐩𝐨𝐫𝐭 dissects the complex fragments of the Market in an easy-to-read manner. This report covers drivers, restraints, challenges, and threats in the Idiopathic Gastroparesis Drugs Market to understand the overall scope of the Market in a detailed yet concise manner.
Additionally, the Market report covers the top-winning strategies implemented by major industry players and technological advancements that steer the growth of the Market.
𝐂𝐥𝐚𝐢𝐦 𝐲𝐨𝐮𝐫 𝐂𝐨𝐩𝐲…
Chronic Idiopathic Myelofibrosis Market 2022 | Detailed Report
The Chronic Idiopathic Myelofibrosis report understands the current and future competitive scenario across types, countries, and applications.It provides accurate, up-to-date analysis of markets and companies.The report use reliable information and analysis to gain a deeper understanding of the current factors impacting the industry.
The Chronic Idiopathic Myelofibrosis report provides exact and accurate data that helps companies of all sizes to make timely decisions. Furthermore, the report provides robust solutions to customers,…
Idiopathic Membranous Nephropathy Treatment Market to Witness Significant Growth …
Idiopathic membranous nephropathy a glomerular disease usually of abrupt onset and associated with the nephrotic syndrome. Membranous nephropathy occurs when the small blood vessels in the kidney (glomeruli), which filter wastes from the blood, become damaged and thickened. As a result, proteins leak from the damaged blood vessels into the urine (proteinuria).
R&D in idiopathic membranous nephropathy is expected to aid in growth of the idiopathic membranous nephropathy treatment market. In…
Global Idiopathic Scoliosis Treatment Market Size by Type (Infantile Idiopathic, …
Global Idiopathic Scoliosis Treatment Market Research report provides vital information related to the overall market and forecast from 2019 to 2026. This report includes the in-depth analysis of market size, share, growth, trends and regional demand and top layers the Idiopathic Scoliosis Treatment Market. The major players dominating the market are focused upon throughout the by analyzing their revenue, their business summary, product segmentation along with the latest developments.
Get Sample…
Chronic Idiopathic Constipation Market Research Report 2024
Constipation can be defined as reduced stool frequency or difficulty in passing stool. The frequency may be reduced to less than three times a week. Reduced or difficult stool passage includes hard lumpy stools, incomplete bowel movements, straining, incomplete evacuation, and need for manual removal of stool. Chronic idiopathic constipation (CIC) can be defined as more chronic or severe continuation of these above symptoms. Many times the cause of constipation…
